- Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
- Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
- Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
- Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
- Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
- Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
- Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
- Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
- Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
- Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
More ▼
Key statistics
As of last trade, Lumos Pharma Inc (LUMO:NMQ) traded at 2.83, 17.43% above the 52 week low of 2.41 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.78 |
---|---|
High | 2.92 |
Low | 2.77 |
Bid | 2.44 |
Offer | 3.00 |
Previous close | 2.83 |
Average volume | 13.69k |
---|---|
Shares outstanding | 8.12m |
Free float | 5.29m |
P/E (TTM) | -- |
Market cap | 22.97m USD |
EPS (TTM) | -4.19 USD |
Data delayed at least 15 minutes, as of Apr 29 2024 20:54 BST.
More ▼